Short answer
Pulmonx Corp (LUNG) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Pulmonx announced financial results for Q2 fiscal 2026 ended June 30, 2026.
Pulmonx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Pulmonx announced financial results for Q2 fiscal 2026 ended June 30, 2026
- Full revenue, profitability, cash flow and guidance details appear in Exhibit 99.1, the attached earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $22.8M, down 5% YoY, with U.S. revenue $14.2M down 4%
- International revenue $8.6M, down 6%, primarily from absent China sales pending registration renewal
- International revenue excluding China grew 12% YoY, indicating underlying overseas commercial momentum
- Record gross margin 78% versus 72%, while operating expenses fell 16% to $26.8M
- Net loss narrowed to $10.1M and adjusted EBITDA loss to $5.1M, but cash fell to $55.8M as of June 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pulmonx Corp 8-K filings
Get the next LUNG 8-K as it lands
Follow LUNG for push alerts, or ask the research agent what this filing means.